Analysts expect Dynavax Technologies Co. (NASDAQ:DVAX) to post earnings of ($0.60) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Dynavax Technologies’ earnings. The lowest EPS estimate is ($0.69) and the highest is ($0.51). Dynavax Technologies reported earnings of ($0.63) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 4.8%. The business is scheduled to announce its next quarterly earnings results on Tuesday, May 14th.

According to Zacks, analysts expect that Dynavax Technologies will report full-year earnings of ($2.10) per share for the current financial year, with EPS estimates ranging from ($2.72) to ($1.44). For the next financial year, analysts expect that the firm will post earnings of ($1.37) per share, with EPS estimates ranging from ($1.85) to ($0.72). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Dynavax Technologies had a negative return on equity of 139.00% and a negative net margin of 1,938.27%. The business had revenue of $3.90 million for the quarter, compared to analyst estimates of $3.43 million. During the same period last year, the business posted ($0.45) EPS. Dynavax Technologies’s revenue was up 18471.4% on a year-over-year basis.

A number of research analysts recently issued reports on DVAX shares. Zacks Investment Research downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Thursday, December 13th. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 price target (down previously from $32.00) on shares of Dynavax Technologies in a research note on Tuesday, February 26th. ValuEngine downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. Finally, BidaskClub downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Three investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $27.00.

In other Dynavax Technologies news, SVP Robert Coffman sold 63,202 shares of Dynavax Technologies stock in a transaction that occurred on Thursday, February 28th. The stock was sold at an average price of $9.03, for a total value of $570,714.06. Following the transaction, the senior vice president now directly owns 86,268 shares in the company, valued at approximately $779,000.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP David Louis Johnson sold 20,765 shares of Dynavax Technologies stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $9.03, for a total value of $187,507.95. Following the completion of the transaction, the vice president now owns 52,786 shares in the company, valued at $476,657.58. The disclosure for this sale can be found here. Insiders have sold a total of 119,411 shares of company stock worth $1,075,091 in the last 90 days. 3.47% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the business. Falcon Point Capital LLC grew its stake in shares of Dynavax Technologies by 54.5% in the 4th quarter. Falcon Point Capital LLC now owns 30,944 shares of the biopharmaceutical company’s stock valued at $283,000 after purchasing an additional 10,921 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Dynavax Technologies by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,883,887 shares of the biopharmaceutical company’s stock valued at $35,759,000 after purchasing an additional 29,898 shares during the last quarter. Clearbridge Investments LLC grew its stake in shares of Dynavax Technologies by 1,189,548.7% in the 3rd quarter. Clearbridge Investments LLC now owns 904,133 shares of the biopharmaceutical company’s stock valued at $11,211,000 after purchasing an additional 904,057 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Dynavax Technologies in the 3rd quarter valued at approximately $1,292,000. Finally, Franklin Resources Inc. grew its stake in shares of Dynavax Technologies by 8.3% in the 3rd quarter. Franklin Resources Inc. now owns 3,136,406 shares of the biopharmaceutical company’s stock valued at $38,891,000 after purchasing an additional 239,876 shares during the last quarter. Institutional investors own 88.07% of the company’s stock.

Shares of NASDAQ DVAX traded down $0.46 during midday trading on Tuesday, hitting $7.10. 1,390,601 shares of the company’s stock were exchanged, compared to its average volume of 1,586,304. The company has a debt-to-equity ratio of 1.60, a quick ratio of 4.08 and a current ratio of 4.58. Dynavax Technologies has a twelve month low of $7.08 and a twelve month high of $22.80. The firm has a market capitalization of $454.38 million, a PE ratio of -2.78 and a beta of 0.70.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Featured Story: Cost of Equity For A Business, Investors

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.